Shots:
- Septerna & Novo Nordisk to identify, develop & market oral small molecules for obesity, T2D & other cardiometabolic diseases under an exclusive global collaboration & license agreement
- As per the deal, Septerna will receive ~$2.2B, incl. over $200M in upfront & near-term milestones, plus research, development, & commercial milestones, along with net sales-based tiered royalties, while Novo will cover R&D expenses; closing expected in Q2’25
- Companies will launch 4 GPCR-targeted programs, incl. GLP-1, GIP, & glucagon receptors with joint research from discovery to candidate selection. After IND-enabling efforts, Novo will lead global development & marketing, while Septerna may opt for profit share in 1 program instead of milestones & royalties
Ref: Septerna | Image: Novo Nordisk and Septerna| Press Release
Related News:- Novo Nordisk Reports P-III (REAL8) Basket Trial Data of Sogroya for Children with Growth Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
